We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
-5.92%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$2.83B
AUM Growth
-$114M
Cap. Flow
+$174M
Cap. Flow %
6.13%
Top 10 Hldgs %
45.99%
Holding
98
New
13
Increased
2
Reduced
1
Closed
3

Top Buys

Rank Stock Value
1
BMEA icon
Biomea Fusion
BMEA
+$36.9M
2
DAWN
Day One Biopharmaceuticals
DAWN
+$24.8M
3
CNTA
Centessa Pharmaceuticals
CNTA
+$21.3M
4
GHRS icon
GH Research
GHRS
+$20.7M
5
RAIN
Rain Oncology Inc. Common Stock
RAIN
+$20.6M

Top Sells

Rank Stock Value
1
LABD icon
Direxion Daily S&P Biotech Bear 3X ETF
LABD
+$27.2M
2
ARYD
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
+$10.3M
3
VINCU
Vincerx Pharma, Inc. Unit
VINCU
+$8.1M
4
ACHL
Achilles Therapeutics
ACHL
+$2.6K

Sector Composition

Rank Sector Weight
1 Healthcare 97.6%
2 Financials 0.79%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BCAB icon
26
BioAtla
BCAB
$5.46M
$29.1M 1.03%
13,727
– –
RNAM
27
DELISTED
Avidity Biosciences
RNAM
$27.7M 0.98%
1,121,327
– –
CGEM icon
28
Cullinan Oncology
CGEM
$1.01B
$27.7M 0.98%
1,074,082
– –
DAWN
29
DELISTED
Day One Biopharmaceuticals
DAWN
$27.1M 0.96%
+1,189,943
New +$24.8M
AMRN
30
Amarin Corp
AMRN
$298M
$26.3M 0.93%
300,000
– –
PNT
31
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$25.7M 0.91%
2,500,000
+1,000,000
+67% +$10.2M
PASG icon
32
Passage Bio
PASG
$14.4M
$25.5M 0.9%
96,416
– –
KNTE
33
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$24.8M 0.88%
1,065,939
– –
BDTX icon
34
Black Diamond Therapeutics
BDTX
$96.8M
$24.6M 0.87%
2,014,858
– –
KDMN
35
DELISTED
Kadmon Holdings, Inc.
KDMN
$24M 0.85%
6,205,882
– –
FOLD
36
DELISTED
Amicus Therapeutics
FOLD
$22.4M 0.79%
2,325,000
– –
GHRS icon
37
GH Research
GHRS
$1.93B
$22M 0.78%
+1,013,399
New +$20.7M
AGEN
38
Agenus
AGEN
$312M
$22M 0.77%
203,800
– –
KURA icon
39
Kura Oncology
KURA
$800M
$21.9M 0.77%
1,050,289
– –
BMRN icon
40
BioMarin Pharmaceuticals
BMRN
$11.6B
$20.9M 0.74%
250,000
– –
GOSS icon
41
Gossamer Bio
GOSS
$82.9M
$20.8M 0.73%
2,562,358
– –
AKRO
42
DELISTED
Akero Therapeutics
AKRO
$20.6M 0.73%
831,495
– –
CNTA
43
DELISTED
Centessa Pharmaceuticals
CNTA
$20.1M 0.71%
+904,227
New +$21.3M
MREO
44
Mereo BioPharma
MREO
$54.7M
$19.7M 0.7%
6,226,673
– –
EPIX
45
DELISTED
ESSA Pharma
EPIX
$19.6M 0.69%
687,000
– –
ODT
46
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$19.6M 0.69%
5,607,086
– –
CDAK
47
DELISTED
Codiak BioSciences, Inc. Common Stock
CDAK
$19.1M 0.67%
1,030,065
– –
BCEL
48
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$18.8M 0.66%
2,202,333
– –
CERE
49
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$18.3M 0.65%
714,500
– –
RAIN
50
DELISTED
Rain Oncology Inc. Common Stock
RAIN
$18.3M 0.64%
+1,175,000
New +$20.6M
1
2
3 4

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q2 2021 Portfolio in Review

As of Q2 2021, Boxer Capital held 98 positions worth $2.83B, down 3.9% from $2.95B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Boxer Capital deployed $174M of net new capital in Q2 2021, opening 13 new positions and adding to 2 existing holdings. Its largest new stake was Biomea Fusion: 2,088,405 shares worth $32.6M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Achilles Therapeutics, an estimated $2.6K trimmed.

  • Boxer Capital's largest Q2 2021 buy was Biomea Fusion: 2,088,405 shares worth $32.6M.
  • Boxer Capital added most to POINT Biopharma Global Inc. Common Stock in Q2 2021, an estimated $10.2M increase.
  • Boxer Capital's biggest Q2 2021 reduction was Achilles Therapeutics, cutting an estimated $2.6K.
  • Boxer Capital fully exited Direxion Daily S&P Biotech Bear 3X ETF in Q2 2021, selling an estimated $27.2M.
  • Boxer Capital's ten largest holdings make up 46% of its $2.83B portfolio in Q2 2021.
  • Boxer Capital opened 13 new positions and closed 3 in Q2 2021.
  • Boxer Capital's portfolio value fell 3.9% quarter-over-quarter to $2.83B.

Based on Boxer Capital's 13F filing for Q2 2021, filed 16 Aug 2021.